

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3507119

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
MACQUARIE US TRADING LLC	08/28/2015
RECEIVING PARTY DATA	
Name:	KADMON PHARMACEUTICALS, LLC
Street Address:	119 COMMONWEALTH DRIVE
City:	WARRENDALE
State/Country:	PENNSYLVANIA
Postal Code:	15086
PROPERTY NUMBERS Total: 5	
Property Type	Number
Patent Number:	6720000
Patent Number:	7538094
Patent Number:	7723310
Application Number:	13988256
PCT Number:	US1324263
CORRESPONDENCE DATA	
Fax Number:	(212)872-1002
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	212-872-1019
Email:	jjameson@akingump.com, kkoehler@akingump.com
Correspondent Name:	JARED R. JAMESSON
Address Line 1:	ONE BRYANT PARK
Address Line 4:	NEW YORK, NEW YORK 10036
NAME OF SUBMITTER:	KWAN KOEHLER
SIGNATURE:	/Kwan Koehler/
DATE SIGNED:	08/31/2015
Total Attachments: 3	
source=Patent Release - Kadmon Pharm (Non-Convertible)#page1.tif	
source=Patent Release - Kadmon Pharm (Non-Convertible)#page2.tif	
source=Patent Release - Kadmon Pharm (Non-Convertible)#page3.tif	

**TERMINATION AND RELEASE
OF
SECURITY INTEREST IN PATENTS**

THIS TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS, dated as of August 28, 2015, by **Macquarie US Trading LLC**, in its capacity as administrative agent (the "Administrative Agent") in connection with (i) that certain Second Amended And Restated Patent Security Agreement, dated as of June 17, 2013 (the "Recorded Patent Agreement") and (ii) that certain Third Amended And Restated Patent Security Agreement, dated as of November 26, 2014, (which amended and restated the Recorded Patent Agreement (the "Existing Patent Agreement") and, together with the Recorded Patent Agreement, the "Patent Agreements"), each by Kadmon Pharmaceuticals, LLC (the "Grantor") in favor of the Administrative Agent.

WHEREAS, pursuant to the terms of the Patent Agreements, the Grantor granted to the Administrative Agent a security interest in the intellectual property identified on Exhibit A attached hereto (the "Patents");

WHEREAS, the Administrative Agent has agreed to terminate and release its security interest in the Patents as herein provided;

WHEREAS, the Recorded Patent Agreement was recorded in the United States Patent and Trademark Office at Reel/Frame 30678/0514 on June 25, 2015;


NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Administrative Agent hereby terminates, releases and discharges, without recourse, representation or warranty, all of the Administrative Agent's security interest in the Patents of the Grantor, including, without limitation, the patents and patent applications listed on Exhibit A attached hereto, effective as of the date set forth above.

The Administrative Agent hereby acknowledges that this document may be filed along with any other necessary documentation with the United States Patent and Trademark Office, to evidence the termination and release granted herein. The Administrative Agent hereby agrees to deliver any further releases or termination statements as may be reasonably necessary to effect the termination and release contemplated hereby, at the Grantor's expense.

[Remainder of page left intentionally blank]

Macquarie US Trading LLC, as Administrative Agent

By: 
Name: Joshua Karlin
Title: Authorized Signatory

By: 
Name: Anita Chid
Title: Associate Director

Termination and Release of Security Interest in Patents

PATENTS

A. Ribavirin United States Patents and Patent Applications Owned by Kadmon Pharmaceuticals, LLC:

<u>Title</u>	<u>Patent. No. / Publication No.</u>	<u>Issue Date / Publication Date</u>
Process For Producing Wet Ribavirin Pellets	6,720,000	04/13/2004
Composition Containing Ribavirin And Use Thereof	7,538,094	05/26/2009
Large Dose Ribavirin Formulations	7,723,310	05/25/2010
Once Daily Treatment of Hepatitis C with Ribavirin and Taribavirin	PCT/US13/24263	N/A
Once Daily Treatment of Hepatitis C with Ribavirin and Taribavirin	13/988,256	N/A